Marshall Financial Group LLC Makes New $879,000 Investment in United Therapeutics Corporation $UTHR

Marshall Financial Group LLC acquired a new stake in United Therapeutics Corporation (NASDAQ:UTHR) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 1,805 shares of the biotechnology company’s stock, valued at approximately $879,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. WealthCollab LLC raised its position in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. lifted its stake in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares during the last quarter. Wilmington Savings Fund Society FSB boosted its position in United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 49 shares during the period. Abich Financial Wealth Management LLC purchased a new stake in United Therapeutics during the third quarter valued at about $44,000. Finally, Geneos Wealth Management Inc. grew its stake in shares of United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

UTHR has been the subject of a number of recent research reports. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Oppenheimer raised their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. UBS Group lifted their price target on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Bank of America reiterated a “neutral” rating on shares of United Therapeutics in a research report on Wednesday, February 25th. Finally, Royal Bank Of Canada increased their price objective on United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $548.09.

Insider Buying and Selling

In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $489.91, for a total transaction of $4,654,145.00. Following the transaction, the chief executive officer owned 130 shares in the company, valued at approximately $63,688.30. This represents a 98.65% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $479.51, for a total value of $10,788,975.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 318,870 shares of company stock valued at $156,760,844 over the last three months. Corporate insiders own 10.30% of the company’s stock.

United Therapeutics Trading Down 0.5%

Shares of United Therapeutics stock opened at $524.28 on Monday. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $548.12. The company has a market cap of $22.98 billion, a P/E ratio of 18.79, a PEG ratio of 1.89 and a beta of 0.84. The company’s fifty day simple moving average is $490.39 and its two-hundred day simple moving average is $468.92.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping the consensus estimate of $6.78 by $0.92. The firm had revenue of $790.20 million during the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period last year, the company posted $6.19 EPS. Analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.